Effect of long-term B-type natriuretic peptide treatment on left ventricular remodeling and function after myocardial infarction in rats

European Journal of Pharmacology

Volumn 602, Issue 1, 2009, Pages 132-137

  He, Jiangui ^a   Chen, Yili ^a   Huang, Yiyi ^a   Yao, Fengjuan ^a   Wu, Zhongkai ^a   Chen, Shenglong ^a   Wang, Lichun ^a   Xiao, Pingxi ^a   Dai, Gang ^a   Meng, Rongsen ^a   Zhang, Chengxi ^a   Tang, Lilong ^a   Huang, Yuli ^a   Li, Zhiming ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

B type natriuretic peptide; Heart failure; Myocaradial infarction; TGF 1 Smad2 signaling; Ventricular remodeling

Indexed keywords

ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; MESSENGER RNA; NESIRITIDE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LONG TERM CARE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE;

ANGIOTENSIN II; ANIMALS; COLLAGEN; MALE; MYOCARDIAL INFARCTION; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SMAD2 PROTEIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 57249108194     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.064     Document Type: Article

References (24)

1. Bettencourt P. Brain natriuretic peptide (nesiritide) in the treatment of heart failure. Cardiovasc. Drug Rev. 20 (2002) 27-36
2. Bujak M., and Frangogiannis N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 74 (2007) 184-195
3. Cataliotti A., Chen H.H., James K.D., and Burnett J.C. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Trends Cardiovasc. Med. 17 (2007) 10-14
4. Chen H.H., Granthama J.A., Schirger J.A., Jougasaki M., Redfield M.M., and Burnett J.C. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J. Am. Coll. Cardiol. 36 (2000) 1706-1712
5. Colucci W.S., Elkayam U., Horton D.P., Abraham W.T., Bourge R.C., Johnson A.D., Wagoner L.E., Givertz M.M., Liang C.S., Neibaur M., Haught W.H., and LeJemtel T.H. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. 343 (2000) 246-253
6. Gray M.O., Long C.S., Kalinyak J.E., Li H.T., and Karliner J.S. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc. Res. 40 (1998) 352-363
7. Hao J., Ju H., Zhao S., Junaid A., Scammell-La Fleur T., and Dixon M. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J. Mol. Cell. Cardiol. 31 (1999) 667-678
8. Hillock R.J., Frampton C.M., Yandle T.G., Troughton R.W., Lainchbury J.G., and Richards A.M. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 94 (2008) 617-622
9. Hobbs R.E., Miller L.W., Bott-Silverman C., James K.B., Rincon G., and Grossbard E.B. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 78 (1996) 896-901
10. Holmes J.W., Borg T.K., and Covell J.W. Structure and mechanics of healing myocardial infarcts. Annu. Rev. Biomed. Eng. 7 (2005) 223-253
11. Jessup M., and Brozena S. Heart failure. N. Engl. J. Med. 348 (2003) 2007-2018
12. Kapoun A.M., Liang F., O'Young G., Damm D.L., Quon D., White R.T., Munson K., Lam V., Schreiner G.F., and Protter A.A. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. 94 (2004) 453-461
13. Kawakami R., Saito Y., Kishimoto I., Harada M., Kuwahara K., Takahashi N., Nakagawa Y., Nakanishi M., Tanimoto K., Usami S., Yasuno S., Kinoshita H., Chusho H., Tamura N., Ogawa Y., and Nakao K. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 110 (2004) 3306-3312
14. Khan R., and Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118 (2006) 10-24
15. Mann D.L., and Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111 (2005) 2837-2849
16. Morita E., Yoshimura M., Ogawa H., Jougasaki M., Matsumura T., Mukoyama M., and Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88 (1993) 82-91
17. Nakanishi M., Saito Y., Kishimoto I., Harada M., Kuwahara K., Takahashi N., Kawakami R., Nakagawa Y., Tanimoto K., Yasuno S., Usami S., Li Y., Adachi Y., Fukamizu A., David L., Garbers D.Y., and Nakao K. Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension 46 (2005) 441-447
18. Redondo S., Ruiz E., Padilla E., Gordillo-Moscoso A., and Tejerina T. Role of TGF-beta1 in vascular smooth muscle cell apoptosis induced by angiotensin II. Eur. J. Pharmacol. 556 (2007) 36-44
19. Schreiner G.F., and Protter A.A. B-type natriuretic peptide for the treatment of congestive heart failure. Curr. Opin. Pharmacol. 2 (2002) 142-147
20. Seo D., and Hare J.M. The transforming growth factor-beta/Smad3 pathway: coming of age as a key participant in cardiac remodeling. Circulation 116 (2007) 2096-2098
21. Sutton M.G., and Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101 (2000) 2981-2988
22. Tamura N., Ogawa Y., Chusho H., Nakamura K., Nakao K., Suda M., Kasahara M., Hashimoto R., Katsuura G., Mukoyama M., Itoh H., Saito Y., Tanaka I., Otani H., and Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. USA 97 (2000) 4239-4244
23. Tiyyagura S.R., and Pinney S.P. Left ventricular remodeling after myocardial infarction: past, present, and future. Mt. Sinai J. Med. 73 (2006) 840-851
24. Tomita H., Egashira K., Ohara Y., Takemoto M., Koyanagi M., Katoh M., Yamamoto H., Tamaki K., Shimokawa H., and Takeshita A. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32 (1998) 273-279